Administration of the GLS1-specific inhibitors BPTES and CB-839 reduced keratinocyte proliferation and chemokine production, decreased Th17 and γδ Th17-cell differentiation and epidermal proliferation, and improved the splenomegaly and skin lesions in a psoriasis-like mouse model (79). The gene discussed is GLS; the disease is psoriasis.